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Abstract
Background: Up to half of all people with HIV infection have some degree of cognitive impairment. This
impairment is typically mild, but nonetheless often disabling. Although early detection of cognitive impairment
offers the greatest hope of effective intervention, there are important barriers to this goal in most clinical settings.
These include uncertainty about how self-reported cognitive symptoms relate to objective impairments, and the
paucity of bedside measurement tools suitable for mild deficits. Clinicians need guidance in interpreting cognitive
symptoms in this population, and a brief cognitive measurement tool targeted to mild impairment. We addressed
these two problems together here. The objective of this study was to determine the extent to which performance
on cognitive tests and self-reported cognitive symptoms form a unidimensional construct.
Methods: Two hundred three HIV+ individuals completed the Montreal Cognitive Assessment, computerized
cognitive tasks and a questionnaire eliciting cognitive symptoms. Rasch measurement theory was applied to
determine whether patient-reported and performance items could be combined to measure cognition as a
unidimensional latent construct.
Results: Performance-based items and cognitive symptoms are arranged hierarchically along the same continuum
of cognitive ability, forming a measure with thresholds covering a broad spectrum of ability that has good internal
reliability. The cognitive symptoms that fit the measurement model relate to important aspects of everyday life,
providing evidence that the identified construct is meaningful.
Conclusions: This finding lays the foundation for a rapid measure of cognitive ability in people with HIV infection that
is feasible for routine clinical use, and shows that some cognitive symptoms are systematically related to performance
in this population.
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Background
Identification of mild cognitive impairment is increas-
ingly seen as a priority in a variety of disorders that
affect the brain. Even very mild deficits may have func-
tional impacts, for example in individuals working in
demanding jobs, and there is an increasing focus on
intervening at the first signs of decline [1–4]. Interven-
tions aiming to arrest cognitive decline are obviously
best delivered as early as possible, to minimize any
functional sequelae. There is thus a need for accurate
measurement of milder forms of cognitive impairment
suitable for routine clinical use. Existing bedside tools
(such as the Mini Mental State Examination [MMSE]
and the Montreal Cognitive Assessment [MoCA]) are
not sensitive to milder impairment, particularly in con-
ditions other than Alzheimer’s disease. Further, these
tools produce a score suitable for classifying people as
impaired or unimpaired, rather than a measure in the
strict sense of the word [5]. Neuropsychological (NP)
testing can serve as a measure in this sense, and is
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sensitive to mild deficits, but is resource-intensive and
unavailable in many settings.
The cognitive impairment that is now recognized to
occur in 30–50 % of people with HIV infection [2] is
a prototypical example of this clinical challenge. Cog-
nitive deficits are typically mild, but can nonetheless
affect medication adherence, occupational and social
function, and may even accelerate mortality [6–12].
Available screening tools are not sensitive enough to
reliably detect these mild impairments, as they were
developed to screen for the presence of dementia
[13–17]. Milder deficits might be more readily de-
tected by the patients themselves. Patient reports have
clear potential advantages: they reflect observations
over a longer period of time than bedside testing, and
they are, by definition, ecologically valid. However,
there is uncertainty about whether patient-reported
cognitive difficulties relate to impairment measured
on neuropsychological testing, with some suggesting
these concerns are more likely to reflect depression
[18, 19]. Thus, front line clinicians are poorly
equipped to identify those who may need more de-
tailed cognitive assessment, and those who may need
treatment of depression or reassurance. Understand-
ing whether patients’ reports of cognitive difficulties
are part of the same construct as that measured by
performance-based test items is therefore of central
importance in improving cognitive assessment in HIV,
and perhaps in other conditions with similar patterns
of mild cognitive difficulties.
Although cognitive assessment traditionally evaluates
several distinct domains (such as memory and executive
function), often with the aim of “localizing” deficits to
particular brain systems, this approach may be less ap-
propriate in HIV, where deficits appear to arise from
widespread brain dysfunction. The conceptualization of
HIV-related cognitive impairment in these terms leads
to the hypothesis that cognitive ability in HIV can be
conceived of as a single latent construct, at least at the
level of resolution that can be reasonably achieved by
the quick ‘bedside’ cognitive assessment that is needed
for routine care.
In support of this hypothesis, several groups, includ-
ing ours, have demonstrated that items testing a range
of cognitive domains (such as specific aspects of mem-
ory, attention, and executive function) can be com-
bined to create a calibrated measure of a single latent
construct, ‘cognitive ability’, with items ordered by level
of difficulty, rather than clustering according to trad-
itional, localizable domains. This has been shown in
HIV [20, 21], as well as in other neurological condi-
tions [22–31]. This claim is based on the application of
modern psychometric methods, specifically Rasch
Measurement Theory (named after Danish statistician
Georg Rasch), to cognitive performance data [32]. Rasch
Measurement Theory determines the extent to which
individual items relating to a latent construct form a
unidimensional, linear continuum [33]. As applied to
cognition, when the data fit the underlying hierarchical
Rasch model, the ordering of the items (e.g. perform-
ance on cognitive tests), from easiest to most difficult,
provides a method of estimating cognitive ability as a
quantity. This approach creates a measure in the strict
sense, akin to a “ruler” for the latent construct, produ-
cing a quantitative estimate that allows meaningful
comparisons of the scores to be made across individuals
and within individuals over time [34]. As an illustration
of this principle, in two different samples of HIV+ indi-
viduals, we have shown that items drawn from the
MoCA fit a Rasch model, i.e. could be ordered by level
of difficulty, permitting the calculation of a quantitative
total score. However, these items alone were too easy to
precisely measure the two samples we studied, i.e. many
items showed a ceiling effect [20, 21]. In other words,
the set of items was poorly targeted to the cognitive
ability of the people in the sample.
Here, we build on this work, adding a new sample
for more power and asking whether patient-reported
items (e.g. “I forget to take my medication”) fit the
same Rasch model as cognitive performance items. A
positive answer to this question would address three
key issues: First, by linking performance on objective
tests to reported real life ability, it would be a source
of evidence that the cognitive ability construct being
assessed has ecological validity. Second, it would en-
hance the usefulness of the cognitive measure in the
clinic by allowing an initial estimation of cognitive
ability based on self-report, which would inform the
judicious selection of the relevant performance items
when required. Finally, it would address whether
people with HIV infection without overt dementia
have insight into their own cognitive performance, a
question of theoretical importance for understanding
the neurological and psychological basis of HIV-
associated cognitive difficulties. The specific objective
of the study was to estimate the extent to which
performance-based cognitive test items and self-
reported cognitive difficulties form a unidimensional
construct in non-demented HIV+ individuals.
Methods
Participants
Two different samples were combined for the ana-
lysis. The first sample (n = 75) was drawn from pa-
tients with scheduled appointments at the Chronic
Viral Illness Service (CVIS) of the McGill University
Health Center from July 2009 to February 2010; this
sample has been fully described by Koski et al. [20].
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The second sample (n = 102) was randomly selected from
consecutive patients attending either the CVIS or the
Clinique Médicale l’Actuel, a large community clinic serv-
ing the HIV+ population in Montreal, between March and
September 2012. The second sample was enriched by the
targeted recruitment of 26 women.
For both samples, inclusion criteria were: HIV+;
aged between 18 and 65 years; and able to communi-
cate in either English or French. Exclusion criteria
were: clinically-recognized dementia, history of infec-
tion of the central nervous system (CNS) or serious
head injury, other neurologic event, active axis 1 psy-
chiatric disorder, substance abuse or use of psycho-
active medication likely to substantially interfere with
cognition.
Data collection and ethics, consent and permissions
The local Research Ethics Board (McGill University
Health Centre, MUHC, and McGill University) approved
the protocols and all subjects provided informed consent
(Studies 13-047-BMD and PSY-09-030). A trained re-
search assistant administered all tests and questionnaires
in the same session, in either English or French. Clinical
and socio-demographic information were collected through
a semi-structured interview and chart review.
Measurement
The selection of items to be tested for fit to the Rasch
model was informed by the extensive literature on the
cognitive domains typically affected in those with HIV
infection [2, 35–38]. Sources of information about cog-
nitive ability consisted of performance on specific cogni-
tive tests and subjects’ answers to questions related to
cognition.
Cognitive performance was directly assessed with
MoCA items [39] testing the domains of executive func-
tion, naming, memory, attention, language, abstraction
and orientation. The MoCA was developed as a screen-
ing tool for mild cognitive impairment in the older
population and, as anticipated, we have previously
shown that the items are too easy for our younger pa-
tient group that was not selected on the basis of the
presence of cognitive difficulties [20, 21]. In order to in-
crease the level of difficulty, we supplemented the
MoCA items with more demanding computerized tasks
selected from the experimental neuropsychology litera-
ture, again focusing on the cognitive processes typically
affected in HIV: simple reaction time, verbal and visuo-
spatial working memory was assessed with digit span
(forward and backwards) and the Corsi block task (for-
ward and backward) [40], manipulation and updating of
verbal and visuospatial material in working memory was
assessed with the letter 2-back task [41] and digit span
(forward and backwards); choice reaction time and
interference control were assessed with the Eriksen
flanker task [42]. Standard variables were captured for
each task: i.e. reaction time (RT), span, error rates, d’,
depending on the task, as in the published work from
which they were drawn.
Presence of cognitive difficulties was documented
using the 20-item Patient Deficit Questionnaire (PDQ),
which assesses self-reported retrospective memory, pro-
spective memory, attention, organization, and planning
over the previous 4 weeks. The questionnaire pertains
to everyday activities of interest to clinicians, such as
adherence to care (e.g. “I forget to take medication” or
“I forget medical appointments”) and safety (e.g. “I for-
get to turn off the stove”), and elicits cognitive difficul-
ties that are frequent among people living with HIV
(e.g. “trouble with concentration”). Importantly, the
PDQ is brief and can be successfully completed by
people with mild to moderate cognitive impairment.
The ordinal responses on the 20 items are usually
summed to create a total score, with higher scores indi-
cating more difficulty, although here each item was
considered individually [43].
Depressive symptoms were documented by the Beck De-
pression Inventory-II (BDI-II) [44] in the first sample, and
the depression sub-scale of the Hospital Anxiety and De-
pression Scale (HADS-D) [45] in the second sample; trad-
itional cut-offs were applied to define the presence of
depressive disorder (BDI-II score ≥ 14, HADS-D score ≥ 8).
Data analysis
Descriptive statistics were used to characterize the sam-
ple. Each item was scored such that a higher value
reflected a better cognitive ability. Analyses were con-
ducted according to recommended steps [33] and the
RUMM2030 software was used, using the partial-credit
model. Rasch analysis proceeded sequentially, fitting the
MoCA items first (Item Set one), then adding the com-
puterized items (Item Set two), such that the construct
was defined by the performance-based items. Finally, the
PDQ items were entered into the model (Item Set 3). Fit
to the Rasch model was tested for each sequential Item
Set using indices of global fit, fit of individual items and
fit of subjects; p-values ≥ 0.05 indicate that there is a lack
of evidence to reject the underlying hierarchical Rasch
Model. This is in contrast to statistical testing of differ-
ence where one wants to reject the “null”; when the
same test is used as a test of fit, the aim is to not reject
the “null”. If the data fit the Rasch model, there is evi-
dence that the items form a measure, in this case of
“cognitive ability”, with sufficient mathematical proper-
ties. Our sample size of 203 individuals meets criteria
for this purpose [46]. A complete description of Rasch
Measurement Theory can be found elsewhere [47]. Sta-
bility of item calibration across different personal
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factors (termed Differential Item Functioning or DIF)
was tested for age (<45, 45–55, > 55 years), education
(<12, ≥12 years), language of test administration and
rater. DIF is a feature of an item indicating that it is
more or less difficult for certain groups of people; an
item with DIF needs to be reworked, rescored or
deleted.
Validity of the measure was established in several
ways. Criterion validity cannot be ascertained since
there is no gold standard measure of global cognitive
ability (as opposed to a diagnostic classification for
HIV-Associated Neurocognitive Disorder (HAND),
which is not a measure in the strict sense). Evidence of
validity, in Rasch Measurement Theory, is determined
by evidence supporting unidimensionality and internal
reliability, and, in the usual way, showing construct val-
idity. In keeping with usual practice, construct validity
was determined by the ordering of items (with easier
item thresholds expected to be lower on the scale of
“cognitive ability”), and known-groups analysis (with
the assumption that subjects with lower education
should have lower scores than those with higher educa-
tion). Unidimensionality was verified using a principal
component analysis (PCA) of the residuals, and internal
reliability was measured by the Person Separation Index
(PSI) and Cronbach’s alpha.
Results
Two hundred and three participants were recruited.
Table 1 provides the demographic, clinical characteristics,
mean MoCA and PDQ scores of the sample. Current CD4
cell count was within the normal range, and 37 % of this
sample met criteria for depression based on the standard
cut-offs of the screening instruments.
A total of 62 items were sequentially tested for fit to
the Rasch model. Table 2 presents the statistics for glo-
bal fit, location, and reliability for each item-set tested
for fit to the Rasch Model.
The first item-set tested was the 28 items from the
MoCA. Only 23 were retained: 3 were removed because
everyone answered them correctly (lion, year, city), and
as such they do not contribute to measurement; 2 were
deleted because they showed DIF by rater (clock num-
bers and repetition of the longer sentence), reflecting
the difficulty of harmonizing the rating of these items
across examiners. Fit to the Rasch model was con-
firmed for the remaining 23 items with 24 thresholds
(χ2: 47.9; 46df; p = 0.39). Item locations by design are
standardized at 0 logit and, ideally, have a SD of 1; here
the SD was slightly higher at 1.3 logits. Ideally, the
mean location of persons should also be 0 with a SD of
1; the mean person location at 2.3 ± 0.9 logits indicates
that the items were too easy for the sample tested. The
MoCA items alone showed poor internal reliability
(PSI = 0.40) for representing the latent construct, cogni-
tive ability.
The second item-set tested included the 23 fitting
MoCA items and the 14 items from computerized tasks.
After deleting five computerized test items for misfit, fit
to the model was verified (χ2: 69.8; 60df; p = 0.18). The
mean person location was closer to 0 at 1.9 ± 1.1 logits,
and reliability was improved (PSI = 0.69).
Finally, the 20 PDQ items were added to the fitting
items from the performance item set. Fitting and de-
leted items are shown in Table 3. A total of 11 items of
the PDQ were deleted for misfit to the model or be-
cause they were redundant with other items and did
not contribute to measurement. The 9 PDQ items that
fit the model reflected difficulties with attention, retro-
spective memory, prospective memory, and planning.
There was DIF by language for one item (PDQ 15); the
English and French versions of that item were treated
separately. Two additional MoCA items and 1 comput-
erized item were deleted at that stage for misfit (for ex-
ample, one of the two abstraction items: “watch-ruler”).
Measurement characteristics were further improved fol-
lowing inclusion of the PDQ items, resulting in a mean
person location of 1.9 ± 0.7 logits with increased reli-
ability (PSI = 0.73). Global fit to the Rasch model was
confirmed (χ2: 96.3; 76df; p = 0.06).
The final model thus included 37 items: 28 performance-
based items and 9 patient-reported items. These items are
Table 1 Characteristics of the sample
Characteristic Sample (N=203)
Demographics
Sex (male), N (%) 166 (82)
Age (years), Mean ± SD 48.1± 9.7
Education (years), Mean ± SD 15 ± 3.8




Viral load, undetectable, N (%) 182 (90)
Current CD4 (cells/μL), Mean ± SD 588.8 ± 278.2
Nadir CD4 (cells/μL), Mean ± SD 273.7 ± 160.1
Clinical variables
Depressed, N (%)a 76 (37)
PDQ score, Mean ± SD, (0–80)b 25 ±13.9
MoCA score, Mean ± SD, (0–30) 26 ± 2.7
Language of administration, N (%)
English 51 (25)
French 152 (75)
aHADS-D score ≥ 8 or a BDI-II score ≥ 14
bPDQ: Patient Deficit Questionnaire
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shown in Table 4. The computerized tasks are described in
more detail elsewhere [20]. Only one person, a recent im-
migrant from a rural area in a resource-poor country, was
not adequately measured by the model.
The frequency of item thresholds and the distribution of
individuals with lowest to highest “cognitive ability” are
shown in Fig. 1. A measure covering at least −4 to +4
logits (or SD) is considered desirable [48]. In our sample,
the range extends from −5.1 to 4.8 logits. Table 4 presents
the item thresholds in order of “cognitive ability”. The
easiest item threshold is generating 0–4 words on the F
fluency test, and the most difficult is repeating backwards
a sequence of 7–8 blocks on the Corsi test. PDQ
item thresholds, highlighted, are interspersed with the
performance-based items, except at the very top and very
bottom of the scale; they span a wide range of ability and
enrich the item bank at most levels of performance.
Construct validity is supported by the ordering of
items as expected, with MoCA items at the lower end
of the continuum and computer-administered items at
the higher end. Additional evidence for construct valid-
ity is provided by model fit, and by the broad spectrum
of item threshold coverage. In addition, subjects were
grouped as expected: those with ≥ 12 years of education
scored significantly higher than those with < 12 years
of education (mean: 1.95 ± 0.70 logits versus 1.44 ±
0.62; p = 0.0002). Evidence for unidimensionality is
provided by the fact that the first PCA from the
item-person residuals explained only 10 % of the re-
sidual variance. Internal reliability as measured by the
PSI was 0.73 and the Cronbach’s alpha was 0.70.
Discussion
The present study aimed to test whether we could de-
velop a measure of cognitive ability that combines
cognitive symptoms and signs. More specifically, we
asked whether, among HIV+ individuals without
clinically-evident dementia, self-reported items fit the
same Rasch model of cognitive ability measured by
performance items, and whether self-report contrib-
uted additional information to the measurement of
that construct. We found that at least some self-report
items fit the same construct of “cognitive ability” as
measured by performance-based tasks. Rasch Meas-
urement Theory has been previously applied to
performance-based cognitive items [20, 31], and has
also been applied to develop a measure of physical
functioning post-stroke that combines performance
(e.g. the two-minute-walk-test) with self-report items
(e.g. reported difficulty in doing housework) [48]. Our
study shows for the first time that the two sources of
information can be combined in the cognitive domain
Table 3 Items on the PDQ tested and retained for the final
rasch model
Item number Retained in
model
Item content
1 Lose your train of thought when speaking
2 ✓ Have difficulty remembering the names
of people, even ones you have met several
times
3 ✓ Forget what you came into the room for
4 Have trouble getting things organized
5 Have trouble concentrating on what people
are saying during a conversation
6 Forget if you had already done something
7 ✓ Miss appointments and meetings you had
scheduled
8 Have difficulty planning what to do in the day
9 ✓ Have trouble concentrating on things like
watching a television program or reading
a book
10 Forget what you did the night before
11 ✓ Forget the date unless you looked it up
12 Have trouble getting started, even if you
had a lot of things to do
13 Find your mind drifting
14 Forget what you talked about after a
telephone conversation
15 ✓ Forget to do things like turn off the stove or
turn on your alarm clock
16 Feel like your mind went totally blank
17 ✓ Have trouble holding phone numbers in
your head, even for a few seconds
18 Forget what you did last week-end
19 ✓ Forget to take your medication
20 ✓ Have trouble making decisions
Table 2 Measurement characteristics of the three models
Model Items remaining/tested Fit χ2 (p) Item location (logits) Person location (logits) Internal reliabilitya (PSI)
Mean (SD) Mean (SD)
MoCA alone 23/28 47.946df (0.39) 0.0 (1.3) 2.3 (0.9) 0.40
MoCA + computerized items 23/23 + 9/14 69.860df (0.18) 0.0 (1.5) 1.9 (1.1) 0.69
MoCA + computerized items+
PDQ items
21/23 + 8/9 + 9/20 96.376df (0.06) 0.0 (1.4) 1.9 (0.7) 0.73
aInternal reliability or Person Separation Index (PSI) is interpreted as a Cronbach’s alpha
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Table 4 Item thresholds of the final model
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as well, at least in the population we studied: some
self-reported difficulties relate in a predictable manner
to some performance-based items, a finding that has
not been reported before and represents a unique con-
tribution of the application of Rasch measurement
theory. We provide mathematical confirmation that
items from these two sources of information align,
reflecting a single latent construct of “cognitive ability” in
people with HIV without overt dementia. The item set
covers a broad spectrum of ability with good internal reli-
ability. On a linear continuum, both performance-based
and patient-reported items are interspersed across the
range of cognitive ability. The most informative model fit
parameters indicated that including self-report items im-
proved global model fit.
Evidence for construct validity also emerged. The
data fit the Rasch model [49] and the item-person
hierarchy is reliable. Fit to model is judged both sta-
tistically and theoretically, with global fit p-value only
one of several criteria; targeting of the items to the
people is an important consideration and as the com-
puterized and self-report items were added, targeting
and reliability improved without rejecting the model.
In addition, a known-groups analysis confirmed that,
Table 4 Item thresholds of the final model (Continued)
| place.1
|








Thresholds are listed in order of decreasing difficulty: the more difficult thresholds are shown at the top and the easier ones at the bottom. Items are identified by
their item number, followed by their threshold number (Example: PDQ3.2 represents PDQ item 3, 2nd threshold). Abbreviations: ccont: clock contour; chand: clock
hand; corbw: corsi backwards; cubes: copying a cube; date: knowing the date; day: knowing the day of the week; digbwA: digits backwards (form A); digbwB: digit
backwards (form B); digf: digit forward ; flanAcon: flanker test (form A), congruent reaction time; flanA: flanker test (form A) flanker effect; flanBcon: flanker test
(form B) congruent reaction time; Fflu: F fluency; mon: month; ser7A: serial 7 (form A); ser7B: serial 7 (form B); trailA: short trail (form A); trailB: short trail (form B);
mW1-mW5: MoCA memory words recall, 1–5; name2-3: name 2nd and 3rd object from MoCA; place: knowing the place; tapa: MoCA tap on letter a
Fig. 1 Distribution of individuals with lowest to highest “cognitive ability” (top) and of item thresholds (bottom). The mean ability of the persons
in this sample is 1.9 logits, a value above the mean location of items (0 logit) and with the best measurement precision occurring around 0.8
logits. One person was removed for non-fit. There is no floor or ceiling effect
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as expected, participants with less education had
lower scores. We could not assess criterion validity,
as there is no gold standard measure of cognitive
ability in HIV. While consensus criteria do exist for
making a diagnosis of HAND [50], measuring cogni-
tion is distinct from diagnostic classification. As ap-
plied here, measurement aims to describe cognitive
ability in terms of a quasi-continuous “amount” across
the whole range of ability. In contrast, a HAND diag-
nosis involves categorizing people into groups based
on degree of impairment in specific cognitive do-
mains. While in principle these two approaches could
align, we have demonstrated in separate work that, in
fact, there is poor concordance between measurement
of cognitive ability (based on MoCA items) and diag-
nosis of HAND [21]. The present study did not aim
to examine the relationship between these two ap-
proaches, instead focusing on a measurement gap, the
lack of a measure of cognitive ability with a legitimate
total score, as the critical initial step.
Including self-report in a cognitive measure has several
advantages. First, linking performance on objective tests
to reported real life ability is a source of evidence that the
cognitive construct being assessed has ecological validity.
The specific patient-reported items that fit the model as-
sess important real-life activities such as forgetting to take
medication, to attend medical appointments, or to turn
off the stove, or having difficulty making decisions. Fu-
ture work could provide further evidence of ecological
validity through direct observation of real life function,
although there is already evidence linking self-reported
cognitive complaints with objective assessment of
everyday function in HIV [51, 52]. Second, as an initial
step in the measurement of cognition, self-reports are
easy to obtain and can inform the selection of perform-
ance items that are most likely to be informative, mak-
ing the assessment as brief as possible by avoiding
items that are too easy or too difficult for the specific
person. We show that specific self-report items can be
integrated directly into the measurement of cognitive
ability in a given individual. Rasch-developed measures
lend themselves readily to this adaptive administration:
the ladder-like quantification of the items means that
only performance on those items around the person’s
specific “rung” need to be evaluated, saving time with-
out sacrificing precision. This approach also provides a
flexible foundation for further optimizing the set of
items, as additional items can be easily tested and re-
lated to the core set.
Our study has limitations. Although the specific set of
items here defines a unidimensional construct of cognitive
ability, it is by no means the definitive set. While the char-
acteristics of the measure generated in this study are
promising, more items are required at the higher end of
the “cognitive ability” spectrum in order to further im-
prove the precision of the measure; this will be particularly
important to monitor cognition in people with high base-
line cognitive function.
The patient-reported item set studied here was not ori-
ginally developed for use in HIV. While the items address
a range of common cognitive complaints, we do not know
whether these particular items are optimal for eliciting
cognitive difficulties in people living with HIV. Develop-
ment of HIV-specific items may add measurement preci-
sion. Further study is also required to revalidate the
scoring options of the items, establish stability over time,
and assure the performance of the measure in varied sam-
ples. In addition, we cannot assume that the hierarchy of
items would hold in clinical populations that are different
from the one in which it was developed, for example in
people with other neurological disorders or frank HIV-
associated dementia. Poor performance in the absence of
awareness of limitations would presumably change the
interplay between patient-reported and performance-
based items, and so would affect the hierarchy and fit.
However, the greatest unmet clinical need at this point is
for early identification of mild cognitive impairment; the
present study shows that assessment of symptoms and
signs can be combined in this context.
Lack of self-reported difficulties in spite of the pres-
ence of profound cognitive impairment is a feature of
dementia associated with HIV infection and other
neurological conditions. Arriving at a value for cogni-
tive ability based exclusively on self-report would be
inaccurate under those conditions. However, in the
non-demented range of cognitive ability tested here,
we confirmed that self-reports on specific questions
about cognitive performance do provide useful infor-
mation, and relate in an orderly fashion to perform-
ance on objective tests. Importantly, deviation from
that orderly relationship in an individual’s responses
could be used to detect potential loss of insight.
The sample studied here had a relatively high preva-
lence of at least mild depressive symptoms. This is an
advantage in that it demonstrates that patient-reports
and cognitive performance can be aligned on a common
scale even in the presence of depression. However, fur-
ther work would be needed to confirm that the item
hierarchy holds in larger samples, and in samples where
the rates of depression differ markedly from the one
studied here. The recruitment strategies we used likely
yielded a sample with minimal selection bias, fairly rep-
resentative of our clinical population, arguing that the
measure is widely applicable.
Conclusions
In summary, we found that cognition in HIV+ individ-
uals without overt dementia can be conceived of as a
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unitary latent construct, which can be assessed by ascer-
taining cognitive symptoms and signs. The final set of 37
items that fit the model can be administered and scored
in less than 30 min, and provides a useful starting point
for a brief measure of cognition suitable for everyday
clinical use. With further refinement, this will equip cli-
nicians and researchers alike with a method for measur-
ing cognition in people with HIV. Further work can
show how it relates to existing diagnostic classifications
and to real world function. Given that mild memory, ex-
ecutive and attentional difficulties are a feature of several
common neurological and medical disorders, this ap-
proach may also prove to be useful for other conditions
where clinicians face similar cognitive assessment chal-
lenges. The present study is an important first step in
addressing recent calls for accessible, efficient, high qual-
ity cognitive assessment tools feasible for a wide range
of clinical settings.
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